



MDwise PDL Changes August 2009 DUR Board Presentation For Hoosier Healthwise PDL

Additions to PDL with NO Clinical Edits

SYMBICORT[®] (budesonide/formoterol fumarate)
ALBENZA (albendazole)
KEPPRA XR (levetiracetam)
LAMICTAL ODT (lamotrigine)

Additions to PDL with Clinical Edits

Product	Rationale
VYTORIN 10/80 - ST	Addition of VYTORIN 10/80 with a step edit requiring evidence of trial and failure in the prior 35 days to first line products (simvastatin, pravastatin).
RELPAK (eletriptan) - ST	Requires evidence of trial and failure to preferred sumatriptan products.
ZOMIG, ZOMIG ZMT (zolmitriptan) - ST	Requires evidence of trial and failure to preferred sumatriptan products.
EXFORGE HCT - ST	Requires evidence of trial and failure to first-line ACEI in the past 60 days.
SANTYL (collagenase) - PA	Indicated for debridement of chronic dermal ulcers or severely burned areas. Provider must include documentation of the size and location of the wound and authorizations will be granted at 2-month intervals.

Changes to or Additions of Clinical Edits

Product	Rationale
Omeprazole Products (DD interaction) PLAVIX (DD interaction)	A drug-drug interaction is reported between PLAVIX and omeprazole. The DD clinical edit will prospectively deny claims for PLAVIX or omeprazole if the other product is already on a member's medication profile. Pantoprazole will be allowed to process when PLAVIX appears on a member's medication profile.
Azithromycin QLL	Removal of Step Edit and implementation of quantity limit to 1 course of therapy per 30 days.

Remove from PDL

Product	Rationale
RAPTIVA (efalizumab)	Product was removed from the market.